X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (8634) 8634
Book Review (1067) 1067
Publication (352) 352
Book Chapter (40) 40
Conference Proceeding (11) 11
Magazine Article (9) 9
Dissertation (6) 6
Book / eBook (4) 4
Data Set (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (7476) 7476
animals (4433) 4433
male (4322) 4322
levodopa - pharmacology (3959) 3959
humans (3897) 3897
female (2526) 2526
rats (2479) 2479
levodopa (2411) 2411
parkinson's disease (2355) 2355
pharmacology & pharmacy (2225) 2225
neurosciences (2065) 2065
parkinson disease - drug therapy (2063) 2063
levodopa - therapeutic use (1593) 1593
middle aged (1434) 1434
l-dopa (1422) 1422
dopamine (1411) 1411
clinical neurology (1401) 1401
aged (1260) 1260
parkinsons-disease (1211) 1211
dopamine - metabolism (1133) 1133
adult (986) 986
antiparkinson agents - therapeutic use (958) 958
mice (874) 874
levodopa - administration & dosage (850) 850
antiparkinson agents - pharmacology (832) 832
dose-response relationship, drug (827) 827
levodopa - adverse effects (802) 802
dopa (793) 793
time factors (751) 751
parkinson disease - physiopathology (748) 748
levodopa - metabolism (718) 718
motor activity - drug effects (710) 710
rats, sprague-dawley (678) 678
dopamine agents - pharmacology (628) 628
disease models, animal (595) 595
corpus striatum - drug effects (583) 583
basal ganglia (579) 579
corpus striatum - metabolism (578) 578
antiparkinson agents - adverse effects (556) 556
dyskinesia (531) 531
brain (523) 523
parkinsons disease (511) 511
neurology (510) 510
movement disorders (508) 508
motor fluctuations (483) 483
brain - metabolism (471) 471
psychiatry (454) 454
rats, wistar (452) 452
brain - drug effects (443) 443
parkinson disease - metabolism (442) 442
neurons (440) 440
behavior, animal - drug effects (429) 429
double-blind (426) 426
apomorphine - pharmacology (425) 425
levodopa - pharmacokinetics (414) 414
phenols (413) 413
drug interactions (412) 412
abridged index medicus (411) 411
antiparkinson agents - administration & dosage (404) 404
drug therapy, combination (396) 396
dopamine - physiology (393) 393
rats, inbred strains (385) 385
carbidopa - pharmacology (384) 384
analysis (381) 381
biochemistry & molecular biology (380) 380
pharmacokinetics (360) 360
levodopa-induced dyskinesia (358) 358
striatum (352) 352
neurons - drug effects (344) 344
parkinson’s disease (339) 339
neurodegenerative diseases (337) 337
double-blind method (322) 322
disease (311) 311
drug combinations (310) 310
parkinson disease (307) 307
parkinsonian disorders - drug therapy (307) 307
dopamine agonists - pharmacology (306) 306
parkinson disease - complications (305) 305
substantia-nigra (301) 301
treatment outcome (297) 297
oxidopamine (295) 295
therapy (293) 293
6-hydroxydopamine (291) 291
dopamine - pharmacology (287) 287
levodopa-induced dyskinesias (284) 284
pharmacology (284) 284
rat (283) 283
kinetics (277) 277
benserazide - pharmacology (273) 273
receptors, dopamine - drug effects (264) 264
dyskinesia, drug-induced - drug therapy (263) 263
tyrosine 3-monooxygenase - metabolism (259) 259
drug therapy (252) 252
dopamine agonists - therapeutic use (251) 251
enzyme inhibitors - pharmacology (248) 248
research (246) 246
serotonin - metabolism (244) 244
aged, 80 and over (241) 241
substantia nigra - drug effects (240) 240
receptors (239) 239
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (8120) 8120
Russian (150) 150
Japanese (89) 89
French (73) 73
Italian (56) 56
German (53) 53
Spanish (48) 48
Chinese (27) 27
Polish (22) 22
Portuguese (3) 3
Bulgarian (2) 2
Czech (2) 2
Dutch (2) 2
Finnish (2) 2
Hungarian (2) 2
Serbian (2) 2
Slovak (2) 2
Slovenian (2) 2
Ukrainian (2) 2
Danish (1) 1
Hebrew (1) 1
Swedish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Neuron, ISSN 0896-6273, 2004, Volume 42, Issue 6, pp. 939 - 946
Synchronous activation of dopamine neurons, for instance upon presentation of an unexpected rewarding stimulus, results in the release of dopamine from both... 
SYNAPTIC INPUTS | SUBSTANTIA-NIGRA NEURONS | DENDRO-DENDRITIC SYNAPSES | POTASSIUM CHANNELS | QUANTAL SIZE | FIRING PATTERN | MEMBRANE-PROPERTIES | DEFICIENT MICE | NEUROSCIENCES | MEDIATED VOLUME TRANSMISSION | VENTRAL TEGMENTAL AREA | Sulpiride - pharmacology | G Protein-Coupled Inwardly-Rectifying Potassium Channels | Mesencephalon - cytology | Calcium - metabolism | Male | Dose-Response Relationship, Drug | Dopamine Agents - pharmacology | Neurons - physiology | Organophosphorus Compounds - pharmacology | Reserpine - pharmacology | Female | Tetrodotoxin - pharmacology | Neurons - drug effects | Electric Stimulation - methods | Action Potentials - drug effects | Dopamine - metabolism | Levodopa - pharmacology | Dopamine Uptake Inhibitors - pharmacology | Mice, Inbred C57BL | Potassium Channels, Inwardly Rectifying | Sodium Channel Blockers - pharmacology | Iontophoresis - methods | Calcium Channel Blockers - pharmacology | Receptors, Dopamine D2 - genetics | GABA Antagonists - pharmacology | Mice, Knockout | Potassium Channels - genetics | Cocaine - pharmacology | Animals | Analysis of Variance | Dopamine Antagonists - pharmacology | Receptors, Dopamine D3 | Adrenergic Uptake Inhibitors - pharmacology | Mice | In Vitro Techniques | Neurons - radiation effects | Dose-Response Relationship, Radiation | Neural Inhibition - drug effects | Dopamine | Neurons | Experiments | Variance analysis | Rodents | Parkinsons disease | Index Medicus
Journal Article
Book
Neuropharmacology, ISSN 0028-3908, 04/2014, Volume 79, pp. 467 - 475
Endocannabinoids (eCBs) modulate synaptic transmission in the brain, but little is known of their regulatory role in nigral dopaminergic neurons, and whether... 
Electrophysiology | Cannabinoids | Parkinson's disease | Synaptic transmission | Dopaminergic | ENDOGENOUS CANNABINOIDS | RAT | SYNAPTIC-TRANSMISSION | ANANDAMIDE | METABOTROPIC GLUTAMATE | DOPAMINERGIC-NEURONS | SELF-INHIBITION | RELEASE | NEUROSCIENCES | PHARMACOLOGY & PHARMACY | DIACYLGLYCEROL LIPASE | RECEPTORS | Endocannabinoids - metabolism | Synaptic Transmission - physiology | Rats, Wistar | Calcium - metabolism | Benzofurans - pharmacology | Receptors, Metabotropic Glutamate - metabolism | Piperidines - pharmacology | Dopamine Agents - pharmacology | Neurons - physiology | Cannabinoid Receptor Antagonists - pharmacology | Dopaminergic Neurons - drug effects | Dopaminergic Neurons - physiology | Synaptic Transmission - drug effects | Neurons - drug effects | Dopamine - metabolism | Guanosine Diphosphate - pharmacology | Pyrazoles - pharmacology | Levodopa - pharmacology | Dopamine - pharmacology | Inhibitory Postsynaptic Potentials - physiology | Rats | Thionucleotides - pharmacology | Arachidonic Acids - pharmacology | Receptor, Cannabinoid, CB1 - metabolism | Substantia Nigra - drug effects | Animals | Dopamine - analogs & derivatives | Guanosine Diphosphate - analogs & derivatives | Central Nervous System Agents - pharmacology | Glutamic Acid - metabolism | Receptor, Cannabinoid, CB1 - antagonists & inhibitors | In Vitro Techniques | Substantia Nigra - physiology | Inhibitory Postsynaptic Potentials - drug effects | Receptors, Metabotropic Glutamate - antagonists & inhibitors | GABA | Glutamate | Gross domestic product | Dopamine receptors | Index Medicus
Journal Article
Life Sciences, ISSN 0024-3205, 2006, Volume 79, Issue 4, pp. 331 - 341
CYP1A2, a principal catalyst for metabolism of various therapeutic drugs and carcinogens, among others, is in part regulated by the stress response. This study... 
Benzo( α)pyrene | Catecholamines | Adrenoceptors | Rat | CYP1A2 | Benzo(α)pyrene | benzo(alpha)pyrene | MEDICINE, RESEARCH & EXPERIMENTAL | catecholamines | rat | BIOACTIVATION | METABOLIC-ACTIVATION | CYTOCHROMES P-450 | ENZYMES | LIVER | PHARMACOLOGY & PHARMACY | HYDROCARBON RECEPTOR | adrenoceptors | RAT-BRAIN | STRESS | NORADRENALINE | Gene Expression Regulation, Enzymologic - drug effects | Up-Regulation | Catecholamines - metabolism | Rats, Wistar | Male | Adrenergic alpha-Antagonists - pharmacology | RNA, Messenger - metabolism | Prazosin - pharmacology | Cytochrome P-450 CYP1A2 - genetics | Sympatholytics - pharmacology | Reserpine - pharmacology | Dexmedetomidine - pharmacology | Benzo(a)pyrene - pharmacology | Oxidoreductases - biosynthesis | Levodopa - pharmacology | Signal Transduction | Oxidoreductases - genetics | Receptors, Adrenergic - metabolism | Rats | Animals | Cytochrome P-450 Enzyme System - biosynthesis | Cytochrome P-450 Enzyme System - genetics | Adrenergic Uptake Inhibitors - pharmacology | Adrenergic alpha-Agonists - pharmacology | Cytochromes | Guanethidine - pharmacology | Epinephrine - pharmacology | Index Medicus | Comparative Study | Reserpine/pharmacology | Cytochrome P-450 Enzyme System/biosynthesis/genetics | Receptors; Adrenergic/metabolism | Dexmedetomidine/pharmacology | Oxidoreductases/biosynthesis/genetics | Research Support; Non-U.S. Gov't | Epinephrine/pharmacology | Guanethidine/pharmacology | Gene Expression Regulation; Enzymologic/drug effects | Cytochrome P-450 CYP1A2/genetics | Rats; Wistar | RNA; Messenger/metabolism | Adrenergic alpha-Agonists/pharmacology | Prazosin/pharmacology | Benzo(a)pyrene/pharmacology | Sympatholytics/pharmacology | Adrenergic Uptake Inhibitors/pharmacology | Catecholamines/metabolism | Adrenergic alpha-Antagonists/pharmacology | Levodopa/pharmacology
Journal Article
British Journal of Pharmacology, ISSN 0007-1188, 02/2012, Volume 165, Issue 4b, pp. 1017 - 1033
Journal Article
Neuropsychopharmacology, ISSN 0893-133X, 2018, Volume 43, Issue 2, pp. 354 - 361
Cortical inhibition (CI) occurs largely through GABA receptor-mediated inhibitory neurotransmission, which can be modulated by cholinergic, dopaminergic, and... 
TMS-EEG | PSYCHIATRY | SCHIZOPHRENIA | GABA(B) RECEPTORS | FAST-SPIKING INTERNEURONS | NEUROSCIENCES | HUMAN MOTOR CORTEX | DEXTROMETHORPHAN | TRANSCRANIAL MAGNETIC STIMULATION | EXCITABILITY | NEURONS | DOPAMINE | PHARMACOLOGY & PHARMACY | Humans | Male | GABA-B Receptor Agonists - administration & dosage | Young Adult | Prefrontal Cortex - drug effects | Levodopa - administration & dosage | Dopamine Agents - pharmacology | Rivastigmine | GABA-B Receptor Agonists - pharmacology | Adult | Female | Dopamine Agents - administration & dosage | Baclofen - pharmacology | Levodopa - pharmacology | Dextromethorphan - pharmacology | Double-Blind Method | Excitatory Amino Acid Antagonists - administration & dosage | Excitatory Amino Acid Antagonists - pharmacology | Transcranial Magnetic Stimulation - methods | Electroencephalography - methods | Cross-Over Studies | Cholinesterase Inhibitors - administration & dosage | Cholinesterase Inhibitors - pharmacology | Neural Inhibition - drug effects | Dextromethorphan - administration & dosage | γ-Aminobutyric acid B receptors | Drugs | Dihydroxyphenylalanine | Cortex (prefrontal) | Transcranial magnetic stimulation | EEG | Dextromethorphan | Pharmacology | Electroencephalography | Drug screening | γ-Aminobutyric acid | Neurotransmitters | Blindness | Baclofen | Glutamatergic transmission | Levodopa | Inhibition | Dopa | Magnetic fields | Neurotransmission | Dopamine receptors | Index Medicus | Original
Journal Article
Journal Article
Neuropsychopharmacology, ISSN 0893-133X, 11/2009, Volume 34, Issue 12, pp. 2477 - 2488
Angiogenesis occurs in the brains of Parkinson's disease patients, but the effects of dopamine replacement therapy on this process have not been examined.... 
Angiogenesis | 6-OHDA | Blood-brain barrier | L-DOPA | Dopamine receptors | Dyskinesia | blood-brain barrier | ROTATIONAL BEHAVIOR | PSYCHIATRY | angiogenesis | BASAL GANGLIA | CEREBRAL GLUCOSE-UTILIZATION | dyskinesia | SUBSTANTIA-NIGRA | NEUROSCIENCES | AUTORADIOGRAPHIC LOCALIZATION | dopamine receptors | ADULT-RAT | NITRIC-OXIDE | PHARMACOLOGY & PHARMACY | INDUCED DYSKINESIA | PARS RETICULATA | ENDOTHELIAL GROWTH-FACTOR | Antiparkinson Agents - pharmacology | Aminoacetonitrile - analogs & derivatives | Extracellular Signal-Regulated MAP Kinases - antagonists & inhibitors | Oxidopamine | Receptors, Dopamine D2 - metabolism | Receptors, Dopamine D1 - metabolism | Protease Inhibitors - pharmacology | Dopamine Agents - pharmacology | Parkinsonian Disorders - drug therapy | Receptors, Dopamine D1 - agonists | Female | Neovascularization, Pathologic - physiopathology | Disease Models, Animal | Receptors, Dopamine D1 - antagonists & inhibitors | Levodopa - pharmacology | Parkinsonian Disorders - physiopathology | Receptors, Dopamine D2 - agonists | Rats | Bromocriptine - pharmacology | Parkinsonian Disorders - chemically induced | Benzazepines - pharmacology | Neovascularization, Pathologic - chemically induced | Basal Ganglia - physiology | Rats, Sprague-Dawley | Animals | Neovascularization, Pathologic - drug therapy | Basal Ganglia - blood supply | 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine - pharmacology | Aminoacetonitrile - pharmacology | Dopamine D2 Receptor Antagonists | Salicylamides - pharmacology | Basal Ganglia - drug effects | Index Medicus | Basic Medicine | Neurosciences | Medical and Health Sciences | Medicin och hälsovetenskap | Medicinska och farmaceutiska grundvetenskaper | Neurovetenskaper
Journal Article
Lancet Neurology, The, ISSN 1474-4422, 2016, Volume 15, Issue 2, pp. 154 - 165
Journal Article
Neuropharmacology, ISSN 0028-3908, 03/2013, Volume 66, pp. 158 - 169
Group III metabotropic glutamate (mGlu) receptors are localized in presynaptic terminals within basal ganglia (BG) circuitry that become hyperactive due to... 
Striatum | Basal ganglia | Akinesia | Rat | Lu AF21934 | l-DOPA-induced dyskinesia | Electrophysiology | HIGH-FREQUENCY STIMULATION | NEUROLOGICAL DISEASES | NEUROSCIENCES | RAT MODEL | STRIATAL SYNAPTIC PLASTICITY | MEDIATED MODULATION | SUBTHALAMIC NUCLEUS | UNILATERAL 6-HYDROXYDOPAMINE LESIONS | PHARMACOLOGY & PHARMACY | DEEP BRAIN-STIMULATION | L-DOPA-induced dyskinesia | MOLECULAR-MECHANISMS | Anilides - therapeutic use | Catalepsy - drug therapy | Synaptic Transmission - physiology | Excitatory Amino Acid Agonists - therapeutic use | Receptors, Metabotropic Glutamate - physiology | Male | Aminobutyrates - pharmacology | Anilides - pharmacokinetics | Parkinson Disease - drug therapy | Oxidopamine | Aminobutyrates - therapeutic use | Excitatory Postsynaptic Potentials - drug effects | Dose-Response Relationship, Drug | Excitatory Postsynaptic Potentials - physiology | Haloperidol - antagonists & inhibitors | Allosteric Regulation - physiology | Dyskinesia, Drug-Induced - drug therapy | Catalepsy - chemically induced | Synaptic Transmission - drug effects | Haloperidol - pharmacology | Disease Models, Animal | Allosteric Regulation - drug effects | Aminobutyrates - agonists | Levodopa - pharmacology | Cyclohexanecarboxylic Acids - therapeutic use | Phosphinic Acids - agonists | Levodopa - therapeutic use | Phosphinic Acids - therapeutic use | Rats | Excitatory Amino Acid Agonists - pharmacology | Rats, Sprague-Dawley | Drug Synergism | Animals | Cyclohexanecarboxylic Acids - pharmacology | Levodopa - adverse effects | Phosphinic Acids - pharmacology | Anilides - pharmacology | Excitatory Amino Acid Agonists - pharmacokinetics | Cyclohexanecarboxylic Acids - pharmacokinetics | Receptors, Metabotropic Glutamate - agonists | Receptors, Metabotropic Glutamate - antagonists & inhibitors | Physiological aspects | Phenols | Amino acids | Parkinson's disease | Glutamate | Drug therapy | Index Medicus | 6-Hydroxydopamine | Phosphinic Acids | Excitatory Amino Acid Agonists | Allosteric Regulation | Catalepsy | Haloperidol | Aminobutyrates | Cellular Biology | Synaptic Transmission | Receptors, Metabotropic Glutamate | Parkinson Disease | Anilides | Life Sciences | Excitatory Postsynaptic Potentials | Cyclohexanecarboxylic Acids | Dyskinesia, Drug-Induced | Levodopa
Journal Article